9 completed, 1 recruiting, 1 terminated. 11 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 9, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow vadadustat: new trials by email Literature Review of vadadustat trials Research Report on vadadustat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury Vadadustat 900mg, Vadadustat 1200mg, Placebo - Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury | Phase 2 / Phase 3 | Recruiting | Paul Potnuru | 1100 | 2025-10-23 | 2026-08-10 |
| Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) vadadustat, placebo - Acute Respiratory Distress Syndrome, Coronavirus Infection | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 448 | 2020-08-22 | 2025-03-26 |
| Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa Vadadustat, Epoetin Alfa, Vadadustat TIW - Anemia, Dialysis-dependent Chronic Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 175 | 2019-01-31 | 2022-09-29 |
| Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents vadadustat, epoetin alfa - Anemia, Dialysis-Dependent Chronic Kidney Disease | Phase 2 | Terminated | Akebia Therapeutics | 2 | 2017-05-02 | 2021-02-21 |
| Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Vadadustat, Placebo - Anemia, Dialysis Dependent Chronic Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 60 | 2016-12-01 | 2021-04-08 |
| Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) Vadadustat, Placebo - Anemia, Non-dialysis Dependent Chronic Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 51 | 2016-10-01 | 2021-04-08 |
| 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis AKB-6548 - Anemia, End Stage Renal Disease | Phase 2 | Completed | Akebia Therapeutics | 94 | 2014-09-10 | 2022-07-01 |
| 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia AKB-6548, Placebo - Anemia, Chronic Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 210 | 2013-07-23 | 2022-07-21 |
| 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia AKB-6548, Placebo - Anemia, Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 93 | 2011-06-15 | 2022-07-01 |
| Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia AKB-6548 - Anemia, Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 10 | 2010-10-21 | 2022-07-01 |
| Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4 Vadadustat - Chronic Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 22 | 2010-07-08 | 2022-06-28 |
Anemia (8) · Renal Insufficiency, Chronic (6) · Renal Insufficiency (4) · Kidney Diseases (2) · COVID-19 (1) · Coronavirus Infections (1) · Kidney Failure, Chronic (1) · Respiratory Distress Syndrome (1)
Akebia Therapeutics (9) · Paul Potnuru (1) · The University of Texas Health Science Center, Houston (1)
United States (9) · Japan (2)
Bentley J. Bobrow, MD (1) · Paul Potnuru, MD (1)